АЛЬФАКАЛЬЦИДОЛ - ПРЕПАРАТС МНОГОКОМПОНЕНТНЫМ ДЕЙСТВИЕМ,направленным на снижение риска переломов и предупреждение падений (обзор литературы)
https://doi.org/10.14341/osteo2008122-28
Список литературы
1. American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic surgeons panel on falls prevention. Guideline for the prevention of falls in older persons. // J. Am. Geriatr Soc, 2001, Vol.49, pp. 664-672
2. Birge S.J., Haddad J.G.: 25-Hydroxycholecalciferol stimulation of muscle metabolism. // J. Clin Invest, 1975, Vol. 56, pp. 1100-1107
3. Bischoff H.A., Borchers M., Gudat F. et al: Un situ detection of 1,25 dihydroxyvitamin D receptor in human skeletal muscle tissue. // Histochem, 2001, Vol.33, pp. 19-24
4. Bischoff-Ferrari H.A., Borchers M., Gudat F., Durmuller U. et al: Vitamin D receptor expression in human muscle tissue decreases with age. // J. Bone Miner Res, 2004, Vol. 19, pp. 265-269
5. Bishoff H.A., Stahelin H.B., Urscheler N. et al: Muscle strength in the elderly: its relation to Vitamin D metabolites. // Arch Phys Med Rehabil, 1999, Vol. 80, pp. 54-58
6. Black D.M., Steinbuch M., Palermo L., Dargent-Molina P., Lindsay R., Hoseyni M.S., et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporosis International, 2001;12:519-28
7. Boland R., de Boland A.R., Marinissen M.J. et al: Avian muscle cells as targets for the secosteroid hormone 1,25 dihydroxyvitamin D3. // J Mol Cell Endocrinol, 1995, Vol. 114, pp.1-8
8. Boland R.: Role of vitamin D in skeletal muscle function. // En- docr Rev, 1986, Vol.7, pp. 434-448
9. Bouxsein M.: Biomechanics of age-related fractures. In Marcus R., Feldman D., Kelsey J. (eds.) // Osteoporosis, second edition. Academic Press San Diego, pp. 509-534
10. Bouxsein M.L., Melton L.J., Rigs B.L., et al.: Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. // J. Bone Miner Res., 2006, Vol. 21, pp. 1475-1482
11. Campbell A.J., Robertson M.C., Gardner M.M. et al.: Randomized controlled trial of a general practice programme of home based exercise to prevent falls in elderly women. // British Medical J, 1997, Vol.315, pp. 1065-1069
12. Campbell A.J., Robertson M.C.: Implementation of multifactorial interventions for fall and fracture prevention. // J. Age and Ageing, 2006, Vol.35-S2, ii60-ii64
13. Campbell A.J., Spears G.F.S., Borrie M.J., Fitzgerald J.L.: Falls, elderly women and the cold. // Gerontology, 1988, Vol. 34, pp.205-208
14. Campbell A.J., Spears G.F.S., Borrie M.J.: Examination by logistic regression of the variables which increase the relative risk of elderly women falling compared to elderly men. [J. Clin Epidemiol., 1990, Vol. 43, pp. 1415-1420
15. Close J., Ellis M., Hooper R. et al.: Prevention of falls in the elderly trial (PROFET): a randomized controlled trial. // Lancet, 1999, Vol. 353, pp. 93-97
16. Costa E.M., Blau H.M., Feldman D.: 1,25-Dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. // Endocrinology, 1986, Vol. 119, pp. 2214-2220
17. Dukas L., Bischoff H.A., Lindpaintner L.S. et al.: Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. // J Am Geri- atr Soc, 2004, Vol. 52, pp. 230-236
18. Dukas L., Schacht E., Mazor Z., Stahelin H.B.: treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of < 5ml/min. // Osteoporosis International, 2005, Vol. 16, pp. 198-203
19. Dukas L., Shacht E., Bischoff H.A.: Better functional mobility in community dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. // J. Nutrition Health and Aging, 2005, Vol.9, pp. 347-351
20. Dukas L.C., Schacht E., Mazor Z., Stahelin H.B.: A new significant and independent risk factor for falls in elderly men and women: a low creatinine clearance of less than 65ml/min. // Osteoporosis International, 2005, Vol.16, pp.332-338
21. Egan M., Jaglal S., Byrne K. et al.: Factors associated with a second hip fracture: a systematic review. // J. Clinical Rehabilitation., 2007, Dec 5 epub ahead of print
22. Endo I., Inoue D., Mitsui T. et al.: Deletion of Vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. // J. Endocrinology, 2003, Vol. 144, pp. 5138-5144
23. Gallagher J.C., Fowler S.E., Detter J.R., Sherman S.S.: Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. // J. Clin Endocrinol Metab, 2001, Vol. 86, pp. 3618-3628
24. Gallagher J.C.: The effects of calcitriol on falls and fractures and physical performance tests. // J. Steroid Biochem Mol Biol, 2004, Vol. 89-90, pp. 497-501
25. Gerdhem P., Ringsberg K.A.M. et al.: Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA study of elderly women. // J. Osteoporosis International, 2005, Vol.16, pp.1425-1431
26. Greenspan S.L., Myers E.R., Maitland L.A. et al.: Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. // JAMA., 1994, Vol. 271, pp. 128-123
27. Helden S., Geel A.C., Geusens P.P. et al.: Bone and fall-related fracture risks in women and men with a recent clinical fracture. // J. Bone Joint Surg Am., 2008, Vol.90, pp.241-248
28. Holick M.F., Matsuoka L.Y., Wortsman J.: Age, vitamin D, and solar ultraviolet (letter) // J. Lancet, 1989, Vol. 2, pp. 1104-1105
29. IOF World Osteoporosis Days, Bangkok, Thailand, 2008, December 3-7
30. Ito M., Azuma Y., Takagli H. et al.: Curative effects of combined treatment with alendronate and 1a-Hydroxyvitamin D3 on bone loss by ovariectomy in aged rats. // Jpn J. Pharmacol, 2002, Vol. 89, pp. 255-266
31. Jackson C., Gaugris S., Sen S.S., Hosking D.: The effect of chole-calciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis // Q J Med, 2007, Vol.100, pp. 185-192
32. Janssen H.C.J.P., Samson M.M., Verhaar H.H.J.: Vitamin D deficiency, muscle function, and falls in elderly people // Am J Clin Nutr, 2002, Vol. 75, pp. 611-615
33. Jarvinen T.L.N., Sievanen H., Khan K.M. et al.: Shifting the focus in fracture prevention from osteoporosis to falls. // British Medical J., 2008, Vol.336, pp. 124-126
34. Kannus P., Niemi S., Parkkari et al. Why is the age-standardized incidence of low-trauma fractures rising in many elderly populations? J Bone Miner Res 2002, Vol. 17, pp.1363-1367
35. Kannus P., Sievanen H., Palvanen M. et al. Prevention of falls and consequent injuries in elderly people. Lancet 2005, Vol. 366 pp.1885-1893
36. Karkkainen M., Rikkonen T., Kroger H. et al.: Association between functional capacity tests and fractures: an eight-year prospective population-based cohort study. // Osteoporosis International, 2008, published ached of printing
37. Kenny R.A., Richardson D.A., Steen N. et al.: Carotid sinus syndrome: a modifiable risk factor for nonaccidental falls in older adults (SAFE PACE). // J. Am Coll Cardiol, 2001, Vol. 38, pp. 1491-1496
38. Kita K., Hujino K., Nasu T. et al.: A simple protocol for preventing falls and fractures in elderly individuals with musculoskeletal disease. // Osteoporosis Int, 2007, Vol. 18, pp. 611-619
39. Lau K.H.W., Baylink D.J.: Vitamin D therapy of osteoporosis: plain vitamin D therapy vs active vitamin D analog (D-hormone) therapy // Calcific Tissue International, 1999, Vol. 65, pp. 307-310
40. Leipzig R.M., Cumming R.G., Tinetti M.E.: Drugs and falls in older people: a systematic review and meta-analysis. // J. Psychotropic drugs. J Am Geriatr Soc, 1999, Vol.47, pp. 30-39
41. Link T.M., Majumdar S.: Current diagnostic techniques in the evaluation of bone architecture. // Current Osteoporosis report, 2004, Vol.2, pp. 47-52
42. Lips P.: Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implication. // Endocr Rew, 2001, Vol.22, pp. 477-501
43. Masoni A., Morosano M., Tomat M.F. et al.: Association between hip fractures and risk factors for osteoporosis. Multivariate analysis. // Medicina (B Aires), 2007, Vol. 67, pp. 423-428
44. McClung M.R., Geusens P., Miller P.D. et al.: Effect of risendronate on the risk of hip fracture in elderly women. // New England J Medicine, 2001, Vol. 344, pp. 333-340
45. Nakamura K., Oshiki R., Hatakeyama K. et al.: Vitamin D status, postural sway, and the incidence of falls in elderly community-dwelling Japanese women. // Arch Osteoporosis, 2006, Vol.1, pp. 21-27
46. Nevitt M.C., Cummings S.R.: Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. // J. Am Geriatr Soc, 1993, Vol.41, pp.1226-1234
47. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
48. Nordin B.E.C., Need A.G., Morris H.A., Horowitz M.: The special role of «hormonal» forms of vitamin D in the treatment of osteoporosis. // Calcific Tissue International, 1999, Vol. 65, pp. 307-310
49. Ones K., Schacht E., Dukas L., Caglar N.: Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years randomized multiarm controlled trial. // The Internet J endocrinology, 2007, Vol.4, published online
50. Orimo H.: Clinical application of 1a(OH)D3 in Japan. // Aktuel Rheumatol, 1994, Vol. 19 (suppl), pp. 27-
51. Papadimitropoulos E., Wells G., Shea B. et al.: The osteoporosis methodology group, and the osteoporosis research advisory gropup. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. // J. Endocrin Review, 2002, Vol. 23, pp. 560-569
52. Pfeifer M., Sinaki M., Geusens P. et al.: Musculoskeletal rehabilitation in osteoporosis: a review. // J Bone and Mineral Research, 2004, Vol. 19, pp. 1208-1214
53. Poole K.E., Compston J.E. Osteoporosis and its management. BMJ 2006, Vol. 333 pp.1251-1256
54. Province M.A., Hadley E.C., Hornbrook M.C., et.al.: The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FISCIT trials. JAMA., 1995, Vol.273, pp.1341-1347
55. Richy F., Deroisy R., Lecart M.P. et al.: D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis. // Aging Ckin Exp Res, 2005, Vol. 17, pp. 133-142
56. Richy F., Dukas L., Schacht E.: Differential effects of D-Hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. // Calcific Tissue International, 2008, epub ahead of print
57. Richy F., Ethgen O., Bruyere O., Reginster J.-Y.: Efficacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. // Osteoporosis International, 2004, Vol.15, pp.301-310
58. Riggs B.L., Melton L.J., Robb R.A., et.al.: Population based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. // J. Bone Mineral Research, 2004, Vol.19, pp.1945-1954
59. Ringe J.D., Farahmand P., Schacht E., Rozhnal A.: Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis. // Rheumatol Int., 2007, Vol. 27, pp. 425-434
60. Ringe J.D., Schacht E.: Prevention and therapy of osteoporosis: the respective roles of plain vitamin D and alfacalcidol. // Rheumatol Int, 2004, Vol. 24, pp. 189-197].
61. Robbins J., Aragaki A.K., Kooperberg C. et al.: Factors associated with 5-year risk of hip fracture in postmenopausal women. // JAMA., 2007, 2007, Vol.298, pp. 2389-2398
62. Robertson M.C., Delvin N., Gardner M.M., Campbell A.J.: Effectiveness and economic evaluation of a nurse delivered home exercise programme to prevent falls. 1: Randomised controlled trial. // British Medical J, 2001, Vol.322, pp. 697-701
63. Robertson M.C., Gardner M.M., Delvin N. et al.: Effectiveness and economic evaluation of a nurse delivered home exercise programme to prevent falls. 2: Controlled trial in multiple centres. // British Medical J., 2001, Vol. 322, pp. 701-704
64. Robinovitch S.N., Inkster L., Maurer J., Warnick B. Strategies for avoiding hip impact during sideways falls. J Bone Miner Res 2003, Vol.18, pp. 1267-1273
65. Sato Y., Manabe S., Kuno H., Oizumi K.: Amelioration of osteopenia and hypovitaminosis D by 1a-hydroxyvitamin D3 in elderly patients with Parkinson's disease. // J. Neurol Neurosurg Psychiatry, 1999, Vol.66, pp.64-68
66. Sato Y., Maruoka H., Oizumi K.: Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1a-hydroxyvitamin D3 and calcium supplementation. // J. Stroke, 1997, Vol. 28, pp. 736-739
67. Schacht E., Richy F., J.-Y. Reginster.: The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. // J. Musculoskelet Neuronal Interact, 2005, Vol. 5, pp. 273-284
68. Schacht E.: Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. // Calcific Tissue International, 1999, Vol. 65, pp. 317-327
69. Sharla S.H., Schacht E., Bawey S. et al.: Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis. // Arthritis + Rheumа, 2003, Vol. 23, pp. 268-274
70. Sorensen O.H., Lund B.I., Saltin B. et al.: Myopathy in bone loss of ageing: improvement by treatment with 1-alphahydroxycholecalciferol and calcium. // J. Clinical Science, 1979, Vol. 56, pp. 157-161
71. Stone K.L., Seeley D.G., Lui L.Y., Cauley J.A., Ensrud K., Browner W.S., et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 2003 Vol 18, pp.1947-1954
72. Suzuki T., Kim H., Yoshida H., Ishizaki T.: Randomized controlled trial of exercise intervention for the prevention of falls in community-dwelling elderly Japanese women. // J. Bone Mineral Metabolism, 2004, Vol. 22, pp. 602-611
73. Swift C.C.: The role of medical assessment and intervention in the prevention of falls. // J. Age and Ageing, 2006, Vol.35-S2, ii65- ii68
74. Tinetti M.E., Baker D.I., McAvay G., et al.: A multifactorial intervention to reduce the risk of falling among elderly people living in the community. // New England J Medicine, 1994, Vol. 331, pp.821-827
75. US Department of Health and Human Services Bone Health and Osteoporosis: A Report of the Surgeon General US Department of Health and Human Services, Office of the Surgeon General, Rockville, MD, 2004
76. Verhaar H.J.J., Samson M.M., Jansen P.A.F. et al.: Muscle strength, functional mobility and vitamin D in older women. // Aging Clin Exp Res, 2000, Vol. 12, pp. 268-274
77. Wehrli F.W., Saha P.K., Gomberg B.R., et al.: Role of magnetic resonance for assessing structure and function of trabecular bone. // Top Magn Reson Imaging, 2002, Vol. 13, pp. 335-355
78. Wong M.: Raloxifene does not affect neuromuscular-related risk factors for falling or the incidence of falls in postmenopausal women with osteoporosis. // J. Am Geriatr Soc, 2000, Vol. 48, S44
Рецензия
Для цитирования:
, , АЛЬФАКАЛЬЦИДОЛ - ПРЕПАРАТС МНОГОКОМПОНЕНТНЫМ ДЕЙСТВИЕМ,направленным на снижение риска переломов и предупреждение падений (обзор литературы). Остеопороз и остеопатии. 2008;11(1):22-28. https://doi.org/10.14341/osteo2008122-28
For citation:
BELAYa Zh.E., SOSUNOVA N.V., ROZhINSKAYa L.Ya. AL'FAKAL'TsIDOL - PREPARATS MNOGOKOMPONENTNYM DEYSTVIEM,napravlennym na snizhenie riska perelomov i preduprezhdenie padeniy (obzor literatury). Osteoporosis and Bone Diseases. 2008;11(1):22-28. https://doi.org/10.14341/osteo2008122-28

Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).